Edgewise Therapeutics Announces Positive 12-Month Topline Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)
BOULDER, Colo.--(BUSINESS WIRE)--Jun 26, 2023--
Source: joplinglobe.com
Impacting Downstream News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Impacting Downstream. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Impacting Downstream Today - Breaking & Trending Today
Edgewise Therapeutics Announces Positive 12-Month Topline Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)
– Sustained positive trend in North Star Ambulatory Assessment (NSAA) scores relative to BMD natural history – – Significant decreases in levels of serum creatine kinase (CK) and fast skeletal muscle troponin I (TNNI2), enzyme biomarkers associated with skeletal muscle damage– – EDG-5506 was well-tolerated at all doses – – Company continuing to enroll patients with BMD in the CANYON Phase 2 trial which now includes a pivotal cohort called GRAND CANYON – – Edgewise leadership to discuss ARCH findings on Tuesday, June 27 at 8:30 a.m. Eastern ...
Source: marketscreener.com